Genus PLC
LSE:GNS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Genus PLC
Capital Expenditures
Genus PLC
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Genus PLC
LSE:GNS
|
Capital Expenditures
-£18.6m
|
CAGR 3-Years
29%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-2%
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Capital Expenditures
-$2.4m
|
CAGR 3-Years
50%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Capital Expenditures
-£4.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Capital Expenditures
-£4.8m
|
CAGR 3-Years
34%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
|
|
Niox Group PLC
LSE:NIOX
|
Capital Expenditures
-£1.5m
|
CAGR 3-Years
-147%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-17%
|
|
Genus PLC
Glance View
Amidst the rolling countryside of Britain, Genus PLC has quietly but profoundly reshaped the agricultural landscape since its formation. With roots tracing back to the British government's Milk Marketing Board, Genus blossomed into an influential player at the intersection of biotechnology and farming. This was not by chance, but through a strategic evolution into a global pioneer in animal genetics. At the heart of their operations, Genus enhances animal breeding by leveraging cutting-edge science, particularly the technology of selective breeding and genetics. They focus primarily on two types of livestock: bovine (cattle) and porcine (pigs), catering to agricultural sectors worldwide. Essentially, through their subsidiaries—ABS Global, focusing on cattle, and PIC, specializing in pigs—the company maximizes genetic improvements, aiding farmers in producing leaner, more disease-resistant, and ultimately more productive livestock. The business model of Genus PLC revolves around the intricate science of animal genetics and the commercial viability it crafts from this foundation. By developing genetically superior livestock, they provide a distinct competitive advantage to farmers who seek more yield with less resource input. The company harnesses sophisticated techniques like genomics and advanced biotechnologies, including gene editing, to achieve these outcomes. With each genetic line licensed, Genus receives a license fee, ensuring a steady stream of revenue. Additionally, sales channels are bolstered by continuous consultative partnerships with farmers to enhance productivity, cementing a cycle of value that perpetuates mutual growth. By marrying science with agricultural prosperity, Genus PLC remains a vanguard in a field where innovation is as essential as the soil itself.
See Also
What is Genus PLC's Capital Expenditures?
Capital Expenditures
-18.6m
GBP
Based on the financial report for Dec 31, 2025, Genus PLC's Capital Expenditures amounts to -18.6m GBP.
What is Genus PLC's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-2%
Over the last year, the Capital Expenditures growth was -3%. The average annual Capital Expenditures growth rates for Genus PLC have been 29% over the past three years , 5% over the past five years , and -2% over the past ten years .